News

Dr. Galsky discusses combo of nivolumab plus trastuzumab deruxtecan in urothelial carcinoma

Urology Times

New York, NY
(May 09, 2022)

Matthew Galsky, MD, discusses study on the combination of nivolumab plus trastuzumab deruxtecan in urothelial carcinoma.

Tags: Icahn School of Medicine at Mount Sinai, Urology, Matthew Galsky, MD

For Media Inquiries

Phone:

212-241-9200 212-241-9200

Fax:

212-241-6512 212-241-6512

Email:

NewsMedia@mssm.edu

If you are a member of the media and are on deadline, please call the Press Office or page the press officer on call.

View All Media Contacts

For Media Inquiries

Phone:

212-241-9200 212-241-9200

Fax:

212-241-6512 212-241-6512

Email:

NewsMedia@mssm.edu

If you are a member of the media and are on deadline, please call the Press Office or page the press officer on call.

View All Media Contacts